Parkinson's Disease
The Parkinson's Disease pipeline: 119 tracked drugs, 17 approved for this indication.
17 approved / phase 414 Phase 32 Phase 2/334 Phase 211 Phase 1/233 Phase 11 US approval withdrawn7 preclinical / unstaged
Compare the share prices of listed companies in Parkinson's Disease →
Total attributable cost
$25.4B
$24,439/patient
Drug spend
Not yet sourced
All severities (2017 MEPS-anchored estimate) · US
The Parkinson's Disease pipeline
Key trial results for every approved and late-stage drug: Parkinson's Disease results by drug.